SALT LAKE CITY, UT--(Marketwire - January 29, 2008) - Myriad Genetics, Inc. (NASDAQ: MYGN) has completed a Phase 1 human clinical trial of MPC-0920, an orally available, direct thrombin inhibitor. The trial studied healthy volunteers in a single, escalating dose format, to determine the safety, dose range and pharmacokinetics of the drug candidate. The results demonstrate significant biological effect on clotting time and a desirable safety profile following oral administration.
